Q0112 HCPCS code: All potassium hydroxide (koh) preparations
Q0112 is the HCPCS Level II code for all potassium hydroxide (koh) preparations. In 2024 Medicare paid an average of $5.66 per service for Q0112 across 18,043 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 3 per day on outpatient hospital claims. Medicare volume fell 9% from 2022 to 2024 (19,854 to 18,043 services). In 2024, about 3,421 clinicians billed Medicare for Q0112 for 16,273 beneficiaries; Texas, California, Florida accounted for 23% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 21 — Priced on the Clinical Laboratory Fee Schedule |
| BETOS category | T1H |
| Added | 1994-01-01 |
| Last action effective | 1994-01-01 |
Who bills Q0112 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 3,421 |
| Medicare beneficiaries | 16,273 |
| States with claims | 50 |
| Share of services in top 3 states (Texas, California, Florida) | 23% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q0112, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 19,854 | 18,070 | $5.71 | $5.71 |
| 2023 | 18,536 | 16,663 | $5.66 | $5.66 |
| 2024 | 18,043 | 16,273 | $5.66 | $5.66 |
States with the most Q0112 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 1,499 | $5.69 |
| California | 1,365 | $5.61 |
| Florida | 1,322 | $5.69 |
| North Carolina | 1,094 | $5.66 |
| Georgia | 1,039 | $5.66 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 3 | Clinical: Data |
| practitioner claims | 3 | Clinical: Data |
What changed for Q0112
- 1994-01-01: Q0112 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q0112?
Q0112 is the HCPCS Level II code for all potassium hydroxide (koh) preparations. Short descriptor: "Potassium hydroxide preps".
How much does Medicare pay for Q0112?
In 2024, the average Medicare payment was $5.66 per service (average allowed $5.66).
Does Medicare cover Q0112?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of Q0112 can be billed per day?
3 on outpatient hospital claims; 3 on practitioner claims (NCCI medically unlikely edits).
Related Q01 codes
- Q0111 — Wet mounts, including preparations of vaginal, cervical or skin specimens
- Q0113 — Pinworm examinations
- Q0114 — Fern test
- Q0115 — Post-coital direct, qualitative examinations of vaginal or cervical mucous
- Q0138 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
- Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
- Q0144 — Azithromycin dihydrate, oral, capsules/powder, 1 gram
- Q0155 — Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0161 — Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
- Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q0112
- Watch Q0112 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q0112
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.